Heron Therapeutics reported second quarter 2026 results that missed analyst expectations on both the top and bottom lines. Management withdrew its previously issued full-year 2026 financial guidance, citing uncertainty regarding generic entry for its lead product and a shift toward exploring strategic alternatives.
Key Highlights
- Total net revenue reached $37.7 million, failing to meet the $42.19 million consensus estimate despite 9% sequential growth.
- The company withdrew its FY 2026 guidance for revenue and Adjusted EBITDA following a June 2026 court decision regarding CINVANTI patents.
- Acute Care revenue grew 43.9% year-over-year to $15.3 million, driven by a 74% increase in APONVIE sales and 35% growth in ZYNRELEF.
- Oncology Supportive Care revenue declined 15.9% year-over-year to $22.3 million as management paused sales force expansion and tightened spending.
- Heron amended its credit facility with Hercules Capital, resetting covenants through 2027 and initiating a potential $17.5 million principal reduction.